Effect of metformin use on survival in resectable pancreatic cancer: A single-institution experience and review of the literature

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Ambe, Chenwi M ^a   Mahipal, Amit ^a   Fulp, Jimmy ^a   Chen, Lu ^a   Malafaxs, Mokenge P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MALE; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; REVIEW; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; DIET THERAPY; KAPLAN MEIER METHOD; META ANALYSIS; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; HUMANS; KAPLAN-MEIER ESTIMATE; METFORMIN; PANCREATIC NEOPLASMS;

EID: 84962525536     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151632     Document Type: Review

References (32)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9-29. doi: 10. 3322/caac.21208 PMID: 24399786
2. American Cancer Society (2014) Cancer Facts and Figures. Atlanta, GA: American Cancer Society.
3. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308. doi: 10.2337/dc09-1791 PMID: 20299480
4. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258. PMID: 16443869
5. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, et al. (2009) Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 15:2506-2511. PMID: 19469001
6. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305. PMID: 15849206
7. McAuliffe JC, Christein JD (2013) Type 2 diabetes mellitus and pancreatic cancer. Surg Clin North Am 93:619-627. doi: 10.1016/j.suc.2013.02.003 PMID: 23632148
8. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a populationbased case-control study. Cancer Causes Control 20:1617-1622. doi: 10.1007/s10552-009-9407-y PMID: 19653109
9. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777. doi: 10.1007/s00125-009-1440-6 PMID: 19572116
10. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938-1946. doi: 10.1002/cncr.24982 PMID: 20166205
11. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:322-326. doi: 10. 2337/dc09-1380 PMID: 19918015
12. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-488. doi: 10.1053/j.gastro.2009.04.013 PMID: 19375425
13. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625. doi: 10.2337/dc08-2175 PMID: 19564453
14. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 11:20. doi: 10.1186/1471-2407-11-20 PMID: 21241523
15. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18:2905-2912. doi: 10.1158/1078-0432. CCR-11-2994 PMID: 22465831
16. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99. PMID: 15261145
17. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22. PMID: 17613433
18. Bartosch-Harlid A, Andersson R (2010) Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. Pancreatology 10:423-428. doi: 10.1159/000264676 PMID: 20720443
19. Pannala R, Basu A, Petersen GM, Chari ST (2009) New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10:88-95. doi: 10.1016/S1470-2045 (08) 70337-1 PMID: 19111249
20. Godsland IF (2010) Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 118:315-332.
21. Koohestani N, Tran TT, Lee W, Wolever TM, Bruce WR (1997) Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet. Nutr Cancer 29:69-76. PMID: 9383787
22. Tran TT, Medline A, Bruce WR (1996) Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 5:1013-1015. PMID: 8959325
23. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586. doi: 10.1038/sj.onc.1211024 PMID: 18212742
24. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752. PMID: 17638885
25. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC (2011) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15:825-836. doi: 10.1111/j.1582-4934.2010.01083.x PMID: 20455996
26. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E (2009) Metformin disrupts crosstalk between G proteincoupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69:6539-6545. doi: 10.1158/0008-5472. CAN-09-0418 PMID: 19679549
27. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273. PMID: 17062558
28. Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16:2505-2511. doi: 10.1158/1078-0432. CCR-09-2229 PMID: 20388847
29. Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, et al. (2014) Mechanism of Metformin-dependent Inhibition of mTOR and Ras Activity in Pancreatic Cancer: Role of Sp Transcription Factors. J Biol Chem.
30. Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, et al. (2016) PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res.
31. Burney S, Khawaja KI, Saif MW, Masud F (2014) Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP 15:313-316. doi: 10.6092/1590-8577/2677 PMID: 25076330
32. Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, et al. (2015) (Ir) relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clin Cancer Res.